Advertisement
Drug Development
Subscribe to Drug Development
View Sample

FREE Email Newsletter

A new role for “hunger hormone”

October 15, 2013 9:06 am | by Anne Trafton, MIT News Office | News | Comments

About a dozen years ago, scientists discovered that a hormone called ghrelin enhances appetite. Dubbed the “hunger hormone,” ghrelin was quickly targeted by drug companies seeking treatments for obesity—none of which have yet panned out. Neuroscientists have now discovered that ghrelin’s role goes far beyond controlling hunger.

Scotland demonstrates its collaborative approach to cell therapy development

October 14, 2013 9:01 am | by The Associated Press | News | Comments

  Scotland announced that leading industry players, Sistemic and Roslin Cells, are going to work together with Scottish Development International to make the process of undertaking clinical trials in cell therapy easier, faster and more successful in reaching commercial realization.

Gilead Sciences stops successful cancer drug study

October 9, 2013 5:02 pm | by The Associated Press | News | Comments

Gilead Sciences said Wednesday it stopped a late-stage clinical trial of a cancer treatment because it was clear the drug was working. Gilead was studying idelalisib as a treatment for chronic lymphocytic leukemia. The company said an early analysis of data from the study showed that patients who were treated with idelalisib had a longer time before the resumption of disease progression or death.

Advertisement

Bayer says FDA approves lung disease drug Adempas

October 9, 2013 9:58 am | by The Associated Press | News | Comments

Bayer HealthCare said Tuesday its drug Adempas has been approved as a treatment for two types of pulmonary hypertension, or high blood pressure in the arteries of the lungs. Bayer said it is already launching the drug, and called Adempas the first drug approved by the Food and Drug Administration as a treatment for more than one type of the disease.

A better way to make antibody-guided therapies

October 8, 2013 8:12 am | News | Comments

Chemists at The Scripps Research Institute have devised a new technique for connecting drug molecules to antibodies to make advanced therapies. Antibody-drug conjugates are the basis of new therapies on the market that use the target-recognizing ability of antibodies to deliver drug payloads to specific cell types. The new technique allows drug developers to forge more stable conjugates than are possible with current methods.

DNA study points to new heart drug targets

October 7, 2013 7:55 am | News | Comments

A global hunt for genes that influence heart disease risk has uncovered 157 changes in human DNA that alter the levels of cholesterol and other blood fats—a discovery that could lead to new medications. Each of the changes points to genes that can modify levels of cholesterol and other blood fats and are potential drug targets.

Pills made from feces cure serious gut infections

October 3, 2013 11:31 am | by MARILYNN MARCHIONE - AP Chief Medical Writer - Associated Press | News | Comments

Hold your nose and don't spit out your coffee: Doctors have found a way to put healthy people's poop into pills that can cure serious gut infections—a less yucky way to do "fecal transplants." Canadian researchers tried this on 27 patients and cured them all after strong antibiotics failed to help.

U.S. approves first pre-surgical breast cancer drug

September 30, 2013 1:12 pm | by MATTHEW PERRONE - AP Health Writer - Associated Press | News | Comments

A biotech drug from Roche has become the first medicine approved to treat breast cancer before surgery, offering an earlier approach against one of the deadliest forms of the disease. The U.S. Food and Drug Administration (FDA) approved Perjeta for women with a form of early-stage breast cancer who face a high risk of having their cancer spread to other parts of the body.

Advertisement

FDA panel backs drug for early-stage breast cancer

September 12, 2013 2:52 pm | by The Associated Press | News | Comments

Government cancer experts say a drug from Roche has shown effectiveness as a new option to treat breast cancer before tumor-removing surgery. The U.S. Food and Drug Administration panel voted 13-0, with one abstention, that the benefits of Perjeta as an initial treatment for breast cancer outweigh its risks.

Cancer vaccine begins Phase 1 clinical trails

September 10, 2013 8:10 am | News | Comments

A cross-disciplinary team of scientists, engineers and clinicians announced that they have begun a Phase 1 clinical trial of an implantable vaccine to treat melanoma, the most lethal form of skin cancer. The effort is the fruit of a new model of translational research being pursued at Harvard Univ. that integrates the latest cancer research with bio-inspired technology development.

FDA approves Celgene drug for pancreatic cancer

September 6, 2013 7:07 pm | by The Associated Press | News | Comments

Federal regulators have approved Celgene Inc.'s drug Abraxane to treat late-stage pancreatic cancer. In experimental trials, the drug extended the lives of patients by a little less than two months more than those treated with the current standard drug.

J&J tries new cap to curb fatal Tylenol overdoses

August 29, 2013 1:44 pm | by MATTHEW PERRONE - AP Health Writer - Associated Press | News | Comments

Bottles of Tylenol sold in the U.S. will soon bear red warnings alerting users to the potentially fatal risks of taking too much of the popular pain reliever. The unusual step, disclosed by the company that makes Tylenol, comes amid a growing number of lawsuits and pressure from the federal government that could have widespread ramifications for a medicine taken by millions of people every day.

FDA grants priority review to Pharmacyclics drug

August 29, 2013 7:54 am | by The Associated Press | News | Comments

Pharmacyclics is getting a priority review of its blood cancer treatment by federal regulators. A priority review shortens a drug evaluation by the U.S. Food and Drug Administration from 10 months to six. The acceptance of the application triggers a $75 million milestone payment to Pharmacyclics from Johnson & Johnson's Janssen unit.

Advertisement

Small chip to advance the art of drug testing

August 27, 2013 2:43 pm | by Kurt Pfitzer, Lehigh Univ. | News | Comments

Standard drug-testing methods have shortcomings. Animal testing is expensive and unreliable, and the static environment of cells and cultures don’t mimic the behavior of the entire organism. An interdisciplinary research team at Lehigh Univ. is using microscopy and optical tweezers to develop a new finger-sized chip that can study the activities of cells at the nanoscale, possibly offering an alternative to traditional drug testing.

Onyx, Bayer expect new Nexavar decision by Dec. 25

August 27, 2013 11:17 am | by The Associated Press | News | Comments

Onyx Pharmaceuticals and Bayer said Tuesday that regulators will conduct a faster review of their pill Nexavar as a treatment for thyroid cancer. The U.S. Food and Drug Administration (FDA) is reviewing Nexavar as a treatment for locally advanced or metastatic thyroid cancer that doesn't respond to treatment with radioactive iodine. The companies said the FDA expects to complete its review by Dec. 25. to.

Dropout rates for oncology Phase I trials remain under 10%

August 26, 2013 8:12 am | by The Associated Press | News | Comments

The overall dropout rate for oncology Phase I trials is very low at only 8%, a study by Cutting Edge Information found. However dropout rates tend to rise as the number of required visits increases. The study discovered that the average number of patients enrolled for these trials across all therapeutic areas is 47.2.

Nanosensors could aid drug manufacturing

August 19, 2013 7:49 am | by Anne Trafton, MIT News Office | News | Comments

Massachusetts Institute of Technology chemical engineers have discovered that arrays of billions of nanoscale sensors have unique properties that could help pharmaceutical companies produce drugs more safely and efficiently. Using these sensors, the researchers were able to characterize variations in the binding strength of antibody drugs, which hold promise for treating cancer and other diseases.

Immunomedics reports positive study of cancer drug

August 14, 2013 12:23 pm | by The Associated Press | News | Comments

Shares of Immunomedics jumped Wednesday after announcing that its treatment for a type of non-Hodgkin lymphoma helped to extend the lives of patients that used it in combination with another drug. The company said patients with newly diagnosed follicular lymphoma responded well to a combination of its epratuzumab and Roche's drug, Rituxan.

“Smart” nanoparticles to improve drug delivery, DNA self-assembly

August 12, 2013 3:39 pm | by Rob Enslin, Syracuse Univ. | News | Comments

A team of chemists at Syracuse Univ. has used a temperature-sensitive polymer to regulate DNA interactions in both a DNA-mediated assembly system and a DNA-encoded drug-delivery system. Their findings may improve how nanomaterials self-assemble into functional devices and how anticancer drugs, including doxorubicin, are delivered into the body.

Univ. Of Maryland, Baltimore's licensing deals fuel local life sciences community

August 6, 2013 8:30 am | by The Associated Press | News | Comments

Univ. of Maryland Ventures announced agreements between Univ. of Maryland, Baltimore and five different life sciences companies across the Baltimore/Washington metropolitan region. The companies include Rexahn Pharmaceuticals, Plasmonix, IGI Technologies, A&G Pharmaceuticals and BioAssay Works.

Protein surface defects act as drug targets

July 30, 2013 11:49 am | News | Comments

Drug designers now have a new way of designing drug candidates suitable for dislodging unstable water molecules. Previous research treated water as a continuum medium even at interfaces. Researchers in Argentina have built a discrete model that describes water molecules’ partial confinement on the protein’s surface. The area where water is most easily dislodged could be a candidate for drug target research.

Pfizer sells key vaccine cheaply to poor countries

July 29, 2013 6:34 am | by LINDA A. JOHNSON - AP Business Writer - Associated Press | News | Comments

Drugmaker Pfizer Inc. has agreed to provide hundreds of millions of doses of its lucrative vaccine against pneumonia and meningitis at a fraction of the usual price for young children in poor countries. The deal to provide 260 million shots of its Prevnar 13 vaccine for a few dollars each is Pfizer's third agreement under an innovative program.

Injectable “smart sponge” holds promise for controlled drug delivery

July 22, 2013 10:16 am | News | Comments

Researchers have developed a drug delivery technique for diabetes treatment in which a sponge-like material surrounds an insulin core. The sponge expands and contracts in response to blood sugar levels to release insulin as needed. The technique could also be used for targeted drug delivery to cancer cells.

Sigma-Aldrich, Scripps partner to accelerate reagent commercialization

July 18, 2013 9:33 am | News | Comments

On Thursday, Sigma-Aldrich Corp.announced a partnership with The Scripps Research Institute (TSRI) to fund research and provide immediate, day-of-publication access to TSRI researchers’ discoveries for the synthesis and analysis of potential drugs. The partnership promises to eliminate months from the translation of cutting-edge chemistry into widespread applications for drug discovery.

Injectable “smart sponge” hold promise for controlled drug delivery

July 17, 2013 10:18 am | News | Comments

Researchers have developed a drug delivery technique for diabetes treatment in which a sponge-like material surrounds an insulin core. The sponge expands and contracts in response to blood sugar levels to release insulin as needed. The technique could also be used for targeted drug delivery to cancer cells.

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading